Cleveland Clinic is a nonprofit, multispecialty academic medical center integrating outpatient and hospital care with research and education for better patient outcomes and experience. More than 4,500 staff physicians and researchers provide services through 20 patient-centered institutes. Cleveland Clinic is a 6,500-bed healthcare system with a main campus in Cleveland, 22 hospitals and over 220 outpatient locations. The health system includes five hospitals in Southeast Florida with more than 1,000 beds, a medical center for brain health in Las Vegas, a sports and executive health center in Toronto, and a 364-bed hospital in Abu Dhabi. Cleveland Clinic London, a 184-bed hospital, opened in March 2022. Cleveland Clinic is recognized in the U.S. and throughout the world for its expertise and care.
New Cleveland Clinic research reveals how BRCA1 and BRCA2 gene mutations may impact cell communication in breast tissue, furthering the understanding of how cancer develops.
Dr Khouri discusses unmet needs in AL amyloidosis, the potential for birtamimab to become a new frontline standard of care, and the importance of confirming earlier post-hoc results from the VITAL trial in the AFFIRM-AL trial in patients with Mayo stage IV AL amyloidosis with cardiac involvement.
In the real-world setting, cases of ocular adverse effects have emerged with greater frequency both in new and established therapies than has been previously observed in many clinical trials.
Closing out their program on multiple myeloma, expert panelists consider the role of holistic and multidisciplinary care when managing patients within the current paradigm.
Continuing its discussion on clinical trials in multiple myeloma, the panel emphasizes the impact that data may have on the real-world treatment landscape.
Key opinion leaders in multiple myeloma management elucidate the value of clinical trials and share enthusiasm for improving enrollment when possible.
A focused discussion on the regulatory aspects of drug testing and approval, globally, with respect to the setting of multiple myeloma management.
Expert panelists consider best methods in educating patients on their options for therapy following a diagnosis of multiple myeloma.
Comprehensive insight to disparities that may impact a patient’s access to therapy for multiple myeloma and how these may be overcome.
Panelists share a brief discussion on the current treatment armamentarium available to patients with newly diagnosed multiple myeloma.
Experts in multiple myeloma management consider essential tests that aid in the diagnosis and treatment of newly presenting patients.
Brian Gastman MD, discusses how findings from CheckMate76K contributed to the rationale for a biomarker analysis in that trial’s patient population, key findings from this biomarker analysis, and how these findings may inform further research regarding the benefits of immunotherapy in earlier-stage disease.
Aaron T. Gerds, MD, PhD, expands on the potential role of momelotinib in the treatment of patients with myelofibrosis who present with anemia, details the data from MOMENTUM, and explains what FDA approval of momelotinib could mean for the treatment of this patient population.
Logan Roof, MD, discusses the importance of investigating demographic disparities that exist in lung cancer mortality, expands on the results of the population-based CDC database analysis, and discusses potential next steps to address these disparities in the future.
Shilpa Gupta, MD, expands on the updated results from EV-103 in patients with locally advanced or metastatic urothelial carcinoma who are ineligible for cisplatin, and details the next steps for investigating the combination of enfortumab vedotin plus pembrolizumab in the ongoing phase 3 EV-302 trial.
Shared insight from key opinion leaders on educational resources made available to physicians and patients, respectively, regarding multiple myeloma management.
Opening its discussion on key unmet needs in multiple myeloma management, a panel of experts discuss key challenges faced when diagnosing patients with multiple myeloma and review the impact of having a multidisciplinary care team.
Logan Roof, MD, discusses findings from a study investigating trends in lung cancer mortality across different sociodemographic populations and locations in the United States between 1999 and 2020.
Shilpa Gupta, MD, discusses the enrollment criteria used for the phase 1/2 EV-103 trial in patients with locally advanced or metastatic urothelial carcinoma, and highlights next steps for the investigation of the frontline combination of enfortumab vedotin and pembrolizumab in the phase 3 EV-302 trial.